Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27

NCT00487786 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT00487786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00487786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27
Lead sponsor
Achieve Life Sciences
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2007
Completion date
October 31, 2011
Enrollment
64 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms